Belite Bio (BLTE) Intangibles (2024 - 2025)
Belite Bio (BLTE) posted quarterly Intangibles of $19000.0 for Q4 2025, down 38.71% year-over-year from $31000.0 in Q4 2024, and down 20.83% quarter-over-quarter from $24000.0 in Q3 2025.
Belite Bio (BLTE) Intangibles (2024 - 2025) Analysis & Trends
Belite Bio's Intangibles history runs 2 years deep, the most recent figure standing at $19000.0 for Q4 2025.
- In Q4 2025, Intangibles fell 38.71% year-over-year to $19000.0; the TTM figure through Dec 2025 stood at $19000.0 (down 38.71% YoY), while the FY2025 annual figure was $19000.0, down 38.71% from the prior year.
- Intangibles for Q4 2025 stood at $19000.0, down from $24000.0 in the prior quarter.
- The five-year high for Intangibles was $31000.0 in Q4 2024, with the low at $19000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Dec 31, 2024 | 31,000.00 |